Chesley Taft & Associates LLC Has $30.29 Million Stock Holdings in Abbott Laboratories $ABT

Chesley Taft & Associates LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 8.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 241,771 shares of the healthcare product maker’s stock after acquiring an additional 18,609 shares during the quarter. Abbott Laboratories comprises 1.2% of Chesley Taft & Associates LLC’s holdings, making the stock its 22nd largest holding. Chesley Taft & Associates LLC’s holdings in Abbott Laboratories were worth $30,291,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the third quarter valued at $31,000. Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories in the second quarter valued at $32,000. Bridge Generations Wealth Management LLC bought a new stake in Abbott Laboratories during the third quarter valued at $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $38,000. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock worth $353,097 in the last ninety days. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $104.12 on Friday. The business has a 50-day simple moving average of $110.82 and a 200 day simple moving average of $122.06. Abbott Laboratories has a one year low of $102.41 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market capitalization of $181.35 billion, a price-to-earnings ratio of 27.99, a PEG ratio of 1.65 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 67.74%.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of recent analyst reports. Royal Bank Of Canada dropped their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Piper Sandler dropped their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.